NCT05043311UNKNOWNanonymous

A Randomized, Double-blinded, Placebo-controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA Vaccine Against COVID-19.

Sponsor

Source record

Sinocelltech Ltd.

Phase

Source record

PHASE1

Modality

AI-normalized

protein therapy

Target

AI-normalized

SCTV01C, Placebo

Indication / condition

AI-normalized

COVID-19

Intervention

Source record

SCTV01C, Placebo

Related intelligence directories

Indication directory: COVID-19 Modality directory: protein therapy Target directory: SCTV01C

Source & freshness

Source record

NCT ID

NCT05043311

Original source

ClinicalTrials.gov

Source last updated

Jan 25, 2022

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05043311

Title

A Randomized, Double-blinded, Placebo-controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA Vaccine Against COVID-19.

Sponsor

Sinocelltech Ltd.

Status

UNKNOWN

Phase

PHASE1

Condition raw

COVID-19, SARS-CoV-2 Infection

Condition normalized

COVID-19, SARS-CoV-2 Infection

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

SCTV01C, Placebo

Target normalized

SCTV01C, Placebo

Interventions

SCTV01C, Placebo

Public preview

Source record

The objective of this study is to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-blinded, Placebo-controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA Vaccine Against COVID-19.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT05043311

Status

UNKNOWN

Phase

PHASE1

Sponsor

Sinocelltech Ltd.

Executive brief

Investment-Ready Snapshot

The objective of this study is to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJan 25, 2022

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05043311

Indication

COVID-19

Modality

protein therapy

Target

SCTV01C, Placebo

Intervention

SCTV01C, Placebo

Source record